Experimental gene injection targets dry AMD
NCT ID NCT03846193
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a gene therapy called GT005 for dry age-related macular degeneration (AMD), a leading cause of vision loss. The therapy delivers a working gene to the retina via a single injection. The study enrolled 56 people and focused on safety and dosing, but was terminated early. If it works, it could offer a one-time treatment to slow vision loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
GT005 (a gene therapy that delivers a working copy of the complement factor I gene via a single injection under the retina)
What this could lead to
If successful, this could lead to a one-time gene therapy that slows or stops vision loss in people with dry age-related macular degeneration.
What could go wrong
This was a very early (Phase 1/2) trial with only 56 participants, and it was terminated early. The therapy involves a surgical injection into the eye, which carries risks like infection or retinal damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bristol Eye Hospital
Bristol, United Kingdom
-
Cincinnati Eye Institute
Cincinnati, Ohio, 45242, United States
-
Manchester Eye Hospital
Manchester, United Kingdom
-
Mid-Atlantic Retina
Philadelphia, Pennsylvania, 19107, United States
-
Midwest Eye Institute
Indianapolis, Indiana, 46290, United States
-
Moorfields Eye Hospital
London, United Kingdom
-
Ophthalamic Consultants of Boston (OCB)
Boston, Massachusetts, 02114, United States
-
Oxford University Hospital
Oxford, United Kingdom
-
Pepose Vision Institute
Chesterfield, Missouri, 63017, United States
-
Retina Clinic London
London, W1G 7LA, United Kingdom
-
Sierra Eye Associates
Reno, Nevada, 89502, United States
-
Sunderland Eye Infirmary
Sunderland, United Kingdom
-
Wolfe Eye Clinic
West Des Moines, Iowa, 50266, United States